US · Healthcare · Biotechnology
EPS came in at 0.29 against a street estimate of 0.26 — a beat of 11.5%.
Analysts rate CorMedix Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $15.33.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.11% |
| Deep Track Capital, LP | 8.05% |
| Vanguard Capital Management, LLC | 4.02% |
| State Street Corp | 2.97% |
| Royce & Associates, LP | 2.79% |
| Geode Capital Management, LLC | 2.50% |
| UBS Group AG | 2.41% |
| Oberweis Asset Management Inc | 1.70% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • CorMedix announced on October 19, 2026, that the FDA accepted for filing its supplemental New Drug Application (sNDA) for REZZAYO® | 2026-10-19 |
| Quarterly report · Q2 2026 CORMEDIX INC. (CRMD) – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $256.7 million as of June 30, 2026, up from $144.8 million at December | 2026-08-13 |
| Results announced · Q3 2026 CORMEDIX THERAPEUTICS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 consolidated revenue: $101.9 million (up 157% from $39.7 million in Q2 202 | 2026-08-13 |
| Company announcement · Q3 2026 CORMEDIX INC. (CRMD) - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Cormedix Inc., Delaware corporation, trades on Nasdaq Global Market under ticker | 2026-08-07 |
| Company announcement · Q2 2026 CORMEDIX INC. (CRMD) - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial data provided in this filing BUSINESS & SEGMENT HIGHLIGHTS • Company operate | 2026-07-02 |
| Current report · Q2 2026 CORMEDIX INC. (CRMD) - FORM 8-K SUMMARY HEADLINE NUMBERS • Date of Report: June 25, 2026 • Company: CorMedix Inc., Delaware corporation • Stock Excha | 2026-07-01 |
| Quarterly report · Q1 2026 CORMEDIX INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (Q1 2026): $127.4 million vs. $39.1 million in Q1 2025 (+226% YoY) - Product | 2026-05-14 |
| Proxy statement · Q2 2026 CORMEDIX INC. PROXY STATEMENT SUMMARY CEO COMPENSATION • Joseph Todisco (CEO) total compensation for 2025: Exact figures not provided in this docume | 2026-04-29 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CorMedix Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.